foto1 foto2 foto3 foto4 foto5

Our news

  • 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
  • 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
  • 03/04/2019:  Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.

Contact us


+7 985 908 58 18

E-mail: |


Regulatory Events Russia

December 2021
28 29 30 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 1
January 2022
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5

Russian Regulatory News

Bioequivalence studies, therapeutical equivalence trials, phase 1, phase II, phase III clinical trials for drug registration in Russia by CRO Pharegis

Obligatory clinical trials for registration of medicines in Russia

As you know well, Russia has its own procedures for registration of new medicines. One of those national features is registration clinical studies. Every drug product to be registered in Russia should pass local clinical study for its safety and efficacy (under GCP), unless its efficacy and safety had already been studied in multinational clinical study with participation of at least two centers in Russia.

Registration clinical studies

are not required only for very limited groups of medicines like locally confirmed orphan drugs (by separate regulatory procedure according to last amendment to the Drug Law in Russia since July 2015) or generic products having their full registered analogs on the Russian market for more than 20 years.

Clinical trials for registration of original product or biosimilar product in Russia

require extensive clinical study program that includes local phase I, phase II and limited phase III (the latter two phases can be combined into one clinical study in some cases).

Registration clinical studies for generic drugs

imply either conduction of a bioequivalence clinical study on limited number of healthy volunteers (in some cases – patients) or therapeutic equivalence study depending on drug formulation and Russian MoH guidelines for bioequivalence studies.

Requirements for conduction of a clinical study in Russia 

are typical: Clinical Study Protocol, Case Report Form template (CRF), Investigator Brochure, Patient information leaflet with Patient consent form as well as Life and Health Insurance for subjects in Russia should be prepared in Russian language according to MoH official guidelines and National GCP standard.

And for any clinical study project  one should get optimal balance between official Russian regulatory requirements, specifics and possibilities of the clinical centers and patients on the one hand, and your business focus, priorities and market forecast, on the other.

You can contact us sending your request to This email address is being protected from spambots. You need JavaScript enabled to view it. to get fast and free feasibility assessment and calculation of the study budget and timeline. Thanks to our consultants and regulatory experts you will be able to discuss your project in detail for free - to get working solution and understanding of optimal perspedtive for your project.


Regulatory news

Feed not found.

News and press releases

  • EMA and ECDC recommendations on heterologous vaccination courses against COVID-19, , 07/12/2021
  • ICMRA high-level meeting on global health emergencies and regulatory approaches, , 06/12/2021
  • EMA recommends approval for use of RoActemra in adults with severe COVID-19, CHMP, 06/12/2021
  • ICMRA and WHO map out flexibilities used by regulators to respond to the COVID-19 pandemic, , 03/12/2021
Feed not found.